Biotech and Pharma Stocks

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.

BIOTECH & PHARMA

PharmAust secures new lead researcher for phase IIb monepantel trial on canine lymphoma

Creso Pharma’s Halucenex almost doubles synthetic psilocybin supply

Incannex partners with University of WA as additional site for ongoing phase 2b sleep apnoea trial

Osteopore receives European certification for expanded line of bone healing products

Invex Therapeutics narrows its search for preferred CMO to manufacture commercial quantities of Presendin

Creso Pharma acquisition target Halucenex to test efficacy of synthetic liquid psilocybin for use in treatment-resistant PTSD

First subsidised CBD oil shows promise for Incannex Healthcare’s own medical cannabis drugs in Australia

Greenlab joins Purplefarm Genetics to develop next-generation medical cannabis strains

PharmAust continues to progress lead drug monepantel in treating canine and human cancers, COVID-19

Osteopore collars European patent for next generation bone regenerative implant technology

PharmAust’s phase IIb monepantel trial identifies therapeutic window for treatment of canine lymphoma

Invex Therapeutics granted FDA meeting to advance Presendin phase III trial for treating idiopathic intracranial hypertension

Incannex Healthcare plans US regulatory pathway for IHL-675A in treating multiple inflammatory conditions

Creso Pharma’s Halucenex makes deal to create pure psilocybin amid softening regulations

Medlab Clinical’s NanaBis drug dramatically improves cancer bone pain for first patient group in treatment study

Creso Pharma acquisition target Halucenex joins forces with US biotech to explore the use of magic mushrooms in treating mental illness

PharmAust secures $750,000 R&D refund from ATO

Medlab Clinical to be granted European patent for NanoCelle drug delivery platform

PharmAust’s MPL and MPLS drug candidates again indicate antiviral activity in SARS-CoV2

Creso Pharma appoints new business director ahead of US legalisation for recreational cannabis

Creso Pharma’s soon-to-be subsidiary Halucenex executes deal to generate psychedelic extracts in-house